You are here


C04 Modelling hypomethylating therapy for monosomal cytogenetic subgroups of acute myeloid leukemia

DNA hypomethylating agents such as Decitabine are the first approved drugs for treatment of myelodysplastic syndromes. We recently showed that Decitabine also has remarkable activity in poor prognosis of acute myeloid leukemia (AML) with monosomal karyotype. We will investigate the mechanism of action of Decitabine in AML and will optimise the therapeutic index of Decitabine by making use of primary cell models and xenograft mouse models. Our data will improve the, until now very unfavourable, prognosis of these mostly elderly AML patients.

Michael Lübbert

1976 - 1983 Study of Psychology, University of Hamburg
1978 - 1985 Study of Medicine, University of Hamburg
1986 - 1988 Research fellow at UCLA School of Medicine, Division of Haematology/Oncology, Los Angeles, USA
1988 - 1990 Senior Research Fellow, University of Mainz, University Freiburg Medical Centre, Department of Haematology and Oncology
1990 - 1996

Gabriele Greve

2001 - 2010 Study of Biology, Albert-Ludwigs-University of Freiburg
2010 Diploma thesis in Molecular Biology and Genetics, Albert-Ludwigs-University of Freiburg
2010 - present PhD student in the lab of Prof. Dr. Michel Lübbert, Division of Haematology and Oncology, University Freiburg Medical Centre
2017 PhD thesis, Albert-Ludwigs-University of Freiburg


    Subscribe to RSS - C04